Breast cancer cells survive chemotherapy by activating targetable immune-modulatory programs characterized by PD-L1 or CD80. - Shahbandi A; Chiu FY; Ungerleider NA; Kvadas R; Mheidly Z; Sun MJS; Tian D; Waizman DA; Anderson AY; Machado HL; Pursell ZF; Rao SG; et al. (Nature cancer, 2022)